Signoflam

# Signoflam ## Overview - **Classification**: Combination analgesic, non-steroidal anti-inflammatory drug (NSAID) and skeletal muscle relaxant. - **Components**: Often a fixed combination of Diclofenac (NSAID) and Paracetamol (Analgesic/Antipyretic), sometimes Serrapeptase or Chlorzoxazone. - **Mechanism**: Diclofenac inhibits COX enzymes, reducing prostaglandin synthesis; Paracetamol inhibits central prostaglandin synthesis; Chlorzoxazone acts centrally to relax skeletal muscle. ***Note**: Since "Signoflam" is a brand name with variable fixed combinations globally, this profile focuses on a *common* formulation: **Diclofenac + Paracetamol + Chlorzoxazone (or similar muscle relaxant).** Always verify specific regional content.* ## Primary Indications 1. **Acute Pain Relief**: Moderate to severe pain associated with inflammation. 2. **Musculoskeletal Conditions**: Pain and spasm associated with strains, sprains, and orthopedic procedures. 3. **Rheumatic Disorders**: Symptomatic relief in conditions like osteoarthritis and rheumatoid arthritis. ## Adult Dosing ### Standard Dosing (Example based on common components) **Acute Pain and Muscle Spasm** - **Dose**: Diclofenac **50 mg**/Paracetamol **325 mg**/Chlorzoxazone **500 mg** (one tablet). - **Frequency**: Every **8 hours** (three times daily, TID). - **Route**: Oral. - **Duration**: Short-term use, typically **5-7 days**. ### Dose Adjustments - **Renal Impairment**: Caution; Diclofenac metabolite clearance reduced. Avoid if CrCl < 30 mL/min. - **Hepatic Impairment**: **Contraindicated** due to risk of hepatotoxicity from Paracetamol and Diclofenac. - **Elderly Patients**: Start at the **lowest effective dose** due to increased renal and GI risk. Avoid maximum doses. ## Pediatric Dosing ***Warning**: The fixed-dose combination Signoflam is **generally not recommended** for routine pediatric use due to the muscle relaxant component and complex dosing of NSAIDs.* ### Neonates (0-28 days) - **Contraindicated**. NSAIDs and muscle relaxants are generally unsafe. ### Infants (1-12 months) - **Contraindicated**. Safety and efficacy are not established for the combination. ### Children (1-12 years) - **Contraindicated**. Use individual components (Paracetamol or Ibuprofen) under specialist guidance. - **Risk**: Increased risk of Reye's syndrome (if components include salicylate/aspirin) and GI adverse effects. ### Adolescents (13-18 years) - **Dose**: May approach adult dosing if weight > 50 kg and fully skeletally mature. - **Maximum**: Limit duration to **5 days**. ## Safety Information ### Contraindications - **Absolute**: History of hypersensitivity to NSAIDs/Paracetamol or acute asthmatic attacks/urticaria after aspirin/NSAID use. - **Absolute**: Active gastrointestinal (GI) bleeding or peptic ulcer disease. - **Absolute**: Severe hepatic or renal failure (CrCl < 30 mL/min). - **Relative**: Severe uncontrolled heart failure (NYHA Class II-IV). ### Common Adverse Effects - **Very Common (>10%)**: Dizziness, somnolence (due to muscle relaxant). - **Common (1-10%)**: Nausea, vomiting, dyspepsia, abdominal pain, diarrhea. - **Common (1-10%)**: Elevated liver enzymes (transaminases). - **Serious but Rare**: GI ulceration or bleeding, acute liver failure, Stevens-Johnson syndrome (SJS), anaphylaxis. ### Key Drug Interactions - **Warfarin/Anticoagulants**: Increased risk of serious bleeding. Monitor INR closely; consider alternative analgesia. - **Lithium/Digoxin**: Diclofenac can increase serum concentrations. Monitor levels. - **ACE Inhibitors/Diuretics**: Reduced antihypertensive and diuretic effects. Increased risk of nephrotoxicity. - **Alcohol**: Significantly increased risk of hepatotoxicity with Paracetamol component. **Avoid concomitant use.** ## Monitoring & Follow-up - **Before Treatment**: Baseline creatinine, LFTs (ALT/AST). Assess history of GI ulcers or heart disease. - **During Treatment**: Monitor for signs of GI bleeding (dark stools, hematemesis). - **Clinical Signs**: Monitor for dizziness or excessive sedation, especially in the first few days. Discontinue if rash or jaundice develops. ## Clinical Pearls - 💡 **Tip 1**: Due to the muscle relaxant component, counsel patients about potential **driving impairment** or operating heavy machinery. - 💡 **Tip 2**: Always use the **lowest effective dose** for the **shortest duration** possible due to GI and cardiovascular risks associated with Diclofenac. - 💡 **Tip 3**: Ensure the patient is not concurrently taking other products containing Diclofenac or Paracetamol to avoid toxicity and accidental overdose. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.